Sunitinib

Sunitinib

PRELIMINARY SCORE

CURATIVE

NON-CURATIVE

PFS

ADJUSTMENTS

Quality of life

No QoL benefit

Serious and disabling adverse effects

Other adjustments

Sunitinib

SCORE

CURATIVE

Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE

Overall Survival

3

Progression-Free Survival

Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate

Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Endocrine Tumours
Therapeutic Indication: Treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours with disease progression in adults
Experimental Arm: Sunitinib
Control Arm: Placebo

© 2024 | **European Society for Medical Oncology** | ESMO - MCBS 1.1 | All rights reserved worldwide.